BIOCON
|
BIOCON Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.52 | 3.85 | 5.40 | 6.17 | 6.24 |
| CEPS(Rs) | 23.88 | 14.63 | 13.21 | 13.01 | 12.10 |
| DPS(Rs) | 0.50 | 1.50 | 0.50 | - | - |
| Book NAV/Share(Rs) | 162.11 | 146.53 | 68.53 | 62.27 | 54.97 |
| Tax Rate(%) | 14.91 | 28.32 | 21.51 | 20.75 | 25.94 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 21.41 | 18.80 | 18.18 | 18.23 | 19.95 |
| EBIT Margin(%) | 16.74 | 11.67 | 12.80 | 15.76 | 20.31 |
| Pre Tax Margin(%) | 10.22 | 7.96 | 11.98 | 14.95 | 19.28 |
| PAT Margin (%) | 8.69 | 5.70 | 9.40 | 11.85 | 14.28 |
| Cash Profit Margin (%) | 19.20 | 15.57 | 19.32 | 21.86 | 23.05 |
| Performance Ratios | |||||
| ROA(%) | 2.41 | 1.79 | 4.03 | 5.24 | 6.94 |
| ROE(%) | 7.00 | 4.98 | 9.83 | 12.03 | 14.26 |
| ROCE(%) | 7.03 | 5.37 | 8.30 | 10.56 | 14.35 |
| Asset Turnover(x) | 0.28 | 0.31 | 0.43 | 0.44 | 0.49 |
| Sales/Fixed Asset(x) | 0.41 | 0.48 | 0.77 | 0.74 | 0.78 |
| Working Capital/Sales(x) | -83.12 | 2.95 | 1.80 | 2.11 | 4.78 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 2.45 | 2.06 | 1.31 | 1.36 | 1.29 |
| Receivable days | 119.85 | 91.14 | 79.49 | 70.03 | 72.86 |
| Inventory Days | 112.31 | 105.87 | 92.60 | 84.38 | 71.47 |
| Payable days | 376.86 | 271.55 | 209.62 | 230.92 | 231.48 |
| Valuation Parameters | |||||
| PER(x) | 31.01 | 53.54 | 61.95 | 66.25 | 43.40 |
| PCE(x) | 11.06 | 14.11 | 25.33 | 31.42 | 22.36 |
| Price/Book(x) | 1.63 | 1.41 | 4.88 | 6.57 | 4.92 |
| Yield(%) | 0.19 | 0.73 | 0.15 | - | - |
| EV/Net Sales(x) | 3.06 | 3.59 | 5.29 | 7.19 | 5.41 |
| EV/Core EBITDA(x) | 10.85 | 13.90 | 19.85 | 26.93 | 19.32 |
| EV/EBIT(x) | 18.07 | 30.50 | 41.23 | 45.64 | 26.64 |
| EV/CE(x) | 1.27 | 1.13 | 3.25 | 4.29 | 3.65 |
| M Cap / Sales | 2.15 | 2.22 | 4.91 | 6.87 | 5.15 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 32.05 | 36.54 | 14.57 | 13.37 | 14.26 |
| Core EBITDA Growth(%) | 44.21 | 32.28 | 14.45 | 8.09 | 14.72 |
| EBIT Growth(%) | 89.92 | 25.26 | -6.64 | -12.06 | -0.47 |
| PAT Growth(%) | 101.84 | -16.67 | -8.82 | -5.96 | -10.25 |
| EPS Growth(%) | 120.99 | -28.64 | -12.48 | -1.03 | -58.68 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.81 | 1.01 | 0.60 | 0.58 | 0.40 |
| Current Ratio(x) | 0.99 | 1.45 | 2.19 | 1.81 | 1.33 |
| Quick Ratio(x) | 0.67 | 0.95 | 1.59 | 1.36 | 0.97 |
| Interest Cover(x) | 2.57 | 3.14 | 15.54 | 19.50 | 19.72 |
| Total Debt/Mcap(x) | 0.50 | 0.72 | 0.12 | 0.09 | 0.08 |
Compare Financial Ratios of peers of BIOCON
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BIOCON | ₹41,396.7 Cr | -0.9% | 2.5% | 35.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹436,103.0 Cr | 1% | 0.7% | 47.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹153,540.0 Cr | -1.1% | -5.8% | 61.7% | Stock Analytics | |
| CIPLA | ₹119,196.0 Cr | 0.3% | -1.8% | 19.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,752.0 Cr | 6% | 11.8% | 20.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,041.2 Cr | -1.5% | -0.1% | 47% | Stock Analytics | |
BIOCON Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | -0.9% |
2.5% |
35.9% |
| SENSEX | -2.7% |
-0.8% |
9.9% |
You may also like the below Video Courses
